Chugai Pharmaceutical Co., Ltd. (CHGCY)
21.82
-0.37
(-1.67%)
USD |
OTCM |
Aug 24, 16:00
Chugai Pharmaceutical Enterprise Value : 65.99B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 65.99B |
| August 21, 2026 | 67.20B |
| August 20, 2026 | 66.88B |
| August 19, 2026 | 66.91B |
| August 18, 2026 | 64.84B |
| August 17, 2026 | 64.77B |
| August 14, 2026 | 65.10B |
| August 13, 2026 | 67.96B |
| August 12, 2026 | 68.62B |
| August 11, 2026 | 67.27B |
| August 10, 2026 | 67.30B |
| August 07, 2026 | 65.46B |
| August 06, 2026 | 63.42B |
| August 05, 2026 | 62.96B |
| August 04, 2026 | 63.95B |
| August 03, 2026 | 63.75B |
| July 31, 2026 | 65.30B |
| July 30, 2026 | 67.07B |
| July 29, 2026 | 64.67B |
| July 28, 2026 | 64.79B |
| July 27, 2026 | 63.06B |
| July 24, 2026 | 66.15B |
| July 23, 2026 | 66.94B |
| July 22, 2026 | 67.73B |
| July 21, 2026 | 69.34B |
| Date | Value |
|---|---|
| July 20, 2026 | 68.46B |
| July 17, 2026 | 68.59B |
| July 16, 2026 | 67.57B |
| July 15, 2026 | 65.99B |
| July 14, 2026 | 67.63B |
| July 13, 2026 | 67.70B |
| July 10, 2026 | 69.48B |
| July 09, 2026 | 69.31B |
| July 08, 2026 | 68.39B |
| July 07, 2026 | 71.45B |
| July 06, 2026 | 70.73B |
| July 02, 2026 | 71.09B |
| July 01, 2026 | 67.57B |
| June 30, 2026 | 70.13B |
| June 29, 2026 | 72.68B |
| June 26, 2026 | 71.16B |
| June 25, 2026 | 71.39B |
| June 24, 2026 | 70.44B |
| June 23, 2026 | 70.34B |
| June 22, 2026 | 71.33B |
| June 18, 2026 | 71.92B |
| June 17, 2026 | 72.64B |
| June 16, 2026 | 71.69B |
| June 15, 2026 | 73.01B |
| June 12, 2026 | 71.56B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 85.21B |
| Daiichi Sankyo Co., Ltd. | 31.92B |
| Eisai Co., Ltd. | 8.479B |
| Santen Pharmaceutical Co., Ltd. | 3.487B |
| Ono Pharmaceutical Co., Ltd. | 6.571B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 730.02M |
| Revenue (Quarterly) | 2.144B |
| Total Expenses (Quarterly) | 1.414B |
| EPS Diluted (Quarterly) | 0.2218 |
| Gross Profit Margin (Quarterly) | 69.49% |
| Profit Margin (Quarterly) | 34.06% |
| Earnings Yield | 4.25% |
| Operating Earnings Yield | 6.11% |
| Normalized Earnings Yield | 4.453 |